Delhi High Court Reviews Natco Pharma's Challenge to Novartis's Ribociclib Patent
Natco Pharma has challenged the Delhi Patent Office's decision to grant a second patent for the breast cancer drug ribociclib to Novartis and Astex Therapeutics. Natco alleges this new patent unlawfully extends Novartis's market monopoly beyond the expiry of its original patent in 2027, claiming it constitutes double patenting. The Delhi High Court has issued notices to all parties and scheduled further hearings for September 16 to determine the petition's maintainability and address the legal arguments.
First-hand measurement across 2 sources
We measured how 2 outlets covered this story. No outlet gave this story a measurable political slant — there is no left–right reading to report. Overall sentiment is neutral (50/100). Lens Score 52/100.
Outlets measured: economictimes, mint. See how each one headlined and framed the same story in the source comparison below.
AI Analysis
Sentiment was consistent across outlets (50–50/100), indicating broadly factual reporting rather than editorialising.
Coverage timeline
mint broke this story on 5 Aug, 11:27 am. Other outlets followed.
- 1